Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-03
2010-02-09
Kim, Jennifer M (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S317000
Reexamination Certificate
active
07659285
ABSTRACT:
Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.
REFERENCES:
patent: 3983234 (1976-09-01), Sayers
patent: 4138492 (1979-02-01), Noverola et al.
patent: 4255432 (1981-03-01), Kluge et al.
patent: 4332804 (1982-06-01), Clark
patent: 4353900 (1982-10-01), Clark
patent: 4353901 (1982-10-01), Clark
patent: 4367232 (1983-01-01), Boix-Igleasias et al.
patent: 4853394 (1989-08-01), King et al.
patent: 5025013 (1991-06-01), Barreau et al.
patent: 5214055 (1993-05-01), Peglion et al.
patent: 5216165 (1993-06-01), Mobilio et al.
patent: 5461066 (1995-10-01), Gericke et al.
patent: 5595872 (1997-01-01), Wetterau, II et al.
patent: 5621010 (1997-04-01), Sueda et al.
patent: 5707798 (1998-01-01), Brann
patent: 5795894 (1998-08-01), Shue et al.
patent: 5869488 (1999-02-01), Shue et al.
patent: 5877173 (1999-03-01), Olney et al.
patent: 5912132 (1999-06-01), Brann
patent: 5955281 (1999-09-01), Brann
patent: 6107324 (2000-08-01), Behan et al.
patent: 6140509 (2000-10-01), Behan et al.
patent: 6150393 (2000-11-01), Behan et al.
patent: 6358698 (2002-03-01), Weiner et al.
patent: 6756393 (2004-06-01), Andersson et al.
patent: 6815458 (2004-11-01), Andersson et al.
patent: 6911452 (2005-06-01), Schlienger et al.
patent: 7022698 (2006-04-01), Hamied et al.
patent: 7041667 (2006-05-01), Armour et al.
patent: 7115634 (2006-10-01), Thurieau et al.
patent: 7253186 (2007-08-01), Andersson et al.
patent: 2004/0006081 (2004-01-01), Burrows et al.
patent: 2004/0106600 (2004-06-01), Andersson et al.
patent: 2004/0213816 (2004-10-01), Weiner et al.
patent: 2005/0014757 (2005-01-01), Andersson et al.
patent: 2005/0148018 (2005-07-01), Weiner et al.
patent: 2005/0244862 (2005-11-01), Brann
patent: 2005/0256108 (2005-11-01), Schlienger
patent: 2006/0094758 (2006-05-01), Andersson et al.
patent: 2006/0106063 (2006-05-01), Thygesen et al.
patent: 2006/0111399 (2006-05-01), Thygesen et al.
patent: 2006/0194778 (2006-08-01), Andersson et al.
patent: 2006/0194834 (2006-08-01), Andersson et al.
patent: 2006/0199794 (2006-09-01), Schlienger
patent: 2006/0199818 (2006-09-01), Andersson et al.
patent: 2006/0199842 (2006-09-01), Weiner et al.
patent: 2006/0205710 (2006-09-01), Schlienger et al.
patent: 2006/0205722 (2006-09-01), Andersson et al.
patent: 2006/0205780 (2006-09-01), Thygesen et al.
patent: 2006/0205781 (2006-09-01), Thygesen et al.
patent: 2006/0264465 (2006-11-01), Weiner et al.
patent: 2006/0264466 (2006-11-01), Weiner et al.
patent: 2006/0286610 (2006-12-01), Brann
patent: 2006/0292606 (2006-12-01), Brann
patent: 984843 (1976-03-01), None
patent: 0 005 318 (1979-11-01), None
patent: 0 061 333 (1982-09-01), None
patent: 0 379 441 (1990-07-01), None
patent: 0 548 015 (1993-06-01), None
patent: 0 260 070 (1993-08-01), None
patent: 0 625 507 (1994-11-01), None
patent: 2802206 (2001-06-01), None
patent: 157325 (1998-03-01), None
patent: WO 94/27967 (1994-12-01), None
patent: WO 97/08166 (1997-03-01), None
patent: WO 97/11940 (1997-04-01), None
patent: WO 97/38665 (1997-10-01), None
patent: WO 97/38984 (1997-10-01), None
patent: WO 98/11128 (1998-03-01), None
patent: WO 98/17646 (1998-04-01), None
patent: WO 98/44921 (1998-10-01), None
patent: WO 98/50534 (1998-11-01), None
patent: WO 99/52927 (1999-10-01), None
patent: WO 00/23076 (2000-04-01), None
patent: WO 00/56335 (2000-09-01), None
patent: WO 00/59497 (2000-10-01), None
patent: WO 00/69810 (2000-11-01), None
patent: WO 01/44191 (2001-06-01), None
patent: WO 01/66521 (2001-09-01), None
patent: WO 01/87839 (2001-11-01), None
patent: WO 02/079186 (2002-10-01), None
patent: WO 03/057698 (2003-07-01), None
patent: WO 03/057698 (2003-07-01), None
patent: WO 03/062206 (2003-07-01), None
patent: WO 03/062206 (2003-07-01), None
patent: WO 03/070246 (2003-08-01), None
patent: WO 03/086400 (2003-10-01), None
patent: WO 2004/000808 (2003-12-01), None
patent: WO 2004/000808 (2003-12-01), None
patent: WO 2004/064738 (2004-08-01), None
patent: WO 2004/064738 (2004-08-01), None
patent: WO 2004/064753 (2004-08-01), None
patent: WO 2005/063254 (2005-07-01), None
patent: WO 2005/112927 (2005-12-01), None
patent: WO 2006/036874 (2006-04-01), None
patent: WO 2006/037043 (2006-04-01), None
patent: WO 2004/039322 (2007-05-01), None
Kalgutkar, et al. 1995. Selective inhibitors of monoamine oxidase (MAO-A and MAO-B) as probes of its catalytic site and mechanism.Medicinal Research Reviews, 15(4)325-388. XP002034298.
Office Action dated Apr. 25, 2002, from U.S. Appl. No. 09/800,096, now U.S. Pat. No. 6,815,458.
Office Action dated Jan. 21, 2003, from U.S. Appl. No. 09/800,096, now U.S. Pat. No. 6,815,458.
Office Action dated Jul. 15, 2003, from U.S. Appl. No. 09/800,096, now U.S. Pat. No. 6,815,458.
Notice of Allowability dated Dec. 8, 2003, from U.S. Appl. No. 09/800,096, filed Mar. 6, 2001, now U.S. Pat. No. 6,815,458.
Notice of Allowance and Fee(s) Due and Notice of Allowability dated Dec. 6, 2003, from U.S. Appl. No. 10/409,782, filed Apr. 7, 2003, now U.S. Pat. No. 6,756,393.
International Preliminary Examination Report dated Mar. 18, 2003, for PCT/US01/07187.
Office Action dated May 21, 2004, from U.S. Appl. No. 10/329,719, filed Dec. 23, 2002, now U.S. Pat. No. 6,911,452.
Notice of Allowance and Fee(s) Due and Notice of Allowability dated Feb. 11, 2005, from U.S. Appl. No. 10/329,719, filed Dec. 23, 2002, now U.S. Pat. No. 6,911,452.
Office Action dated Jun. 26, 2006, from U.S. Appl. No. 11/154,083, filed Jun. 26, 2006.
Notice of Allowability, Notice of Allowance and Fee(s) Due, and Interview Summary dated Dec. 15, 2006, from U.S. Appl. No. 11/154,083, filed Jun. 16, 2005.
Office Action dated Oct. 5, 2006, from U.S. Appl. No. 11/418,322, filed May 3, 2006.
Office Action dated Jan. 23, 2007, from U.S. Appl. No. 11/418,322, filed May 3, 2006.
Written Opinion dated Sep. 9, 2003, for PCT/US02/41476.
International Preliminary Examination Report dated Jan. 15, 2004, for PCT/US02/41476.
Office Action dated Nov. 4, 2004, from U.S. Appl. No. 10/601,070, filed Jun. 20, 2003.
Notice of Allowance and Fee(s) Due and Notice of Allowability dated Jul. 12, 2005, from U.S. Appl. No. 10/601,070, filed Jun. 20, 2003.
Notice of Allowance and Fee(s) Due and Notice of Allowability dated Mar. 29, 2006, from U.S. Appl. No. 10/601,070, filed Jun. 20, 2003.
International Search Report for PCT/US03/19797 dated Dec. 3, 2003.
Written Opinion for PCT/US03/19797 dated Apr. 5, 2004.
International Preliminary Examination Report for PCT/US03/19797 dated Jul. 28, 2004.
International Search Report for PCT/US2004/001234 dated Sep. 8, 2004.
International Written Opinion for PCT/US2004/001234 dated Sep. 8, 2004.
International Preliminary Report on Patentability for PCT/US2004/001234 dated Apr. 14, 2005.
Adam, et al. 1989. Effects of repeated ritanserin on middle-aged poor sleepers.Psychopharmacology, 99:219-221.
Adell, et al. 2005. Strategies for producing faster acting antidepressants.Drug Discovery Today, 10(8):578-585.
Akin, et al. 2004. Decreased serotonin 5-HT2Areceptor-stimulated phosphoinositide signaling in fibroblasts from melancholic depressed patients.Neuropsychopharmacology, 29:2081-2087.
Alvisi, N. 1892. Sulla formazione di derivati pirazolici dalle dicloridrine e dalla tribromidrina della glicerina ordinaria,Gazz. Chem. Ital. 22:158-168.
Antilla, et al. 2001. Copper-catalyzed coupling of arylboronic acids and amines.Organic Letters, 3(13):2077-2079.
Antilla, et al. 2002. The copper-catalyzedN-arylation of indole
Andersson Carl-Magnus A.
Brann Mark R.
Davis Robert E.
Uldam Allan K.
Weiner David M.
Acadia Pharmaceuticals Inc.
Jones Day
Kim Jennifer M
LandOfFree
Selective serotonin 2A/2C receptor inverse agonists as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective serotonin 2A/2C receptor inverse agonists as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective serotonin 2A/2C receptor inverse agonists as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4157532